Combination Therapy with Pregabalin and Morphine Relieves Dinutuximab-Induced Pain in a 3-Year-Old Girl: A Case Report.

IF 1.3 Q4 HEALTH CARE SCIENCES & SERVICES
Palliative medicine reports Pub Date : 2026-06-07 eCollection Date: 2026-01-01 DOI:10.1177/26892820261452103
Maiko Akazawa, Yuki Shigetsura, Kazuko Kawakatsu, Naomi Matsuyama, Hirohito Kubota, Tomohiro Terada, Kazuki Shimada
{"title":"Combination Therapy with Pregabalin and Morphine Relieves Dinutuximab-Induced Pain in a 3-Year-Old Girl: A Case Report.","authors":"Maiko Akazawa, Yuki Shigetsura, Kazuko Kawakatsu, Naomi Matsuyama, Hirohito Kubota, Tomohiro Terada, Kazuki Shimada","doi":"10.1177/26892820261452103","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Opioids are commonly initiated prior to dinutuximab (DIN)-an anti-disialoganglioside 2 antibody used in the treatment of neuroblastoma-and continued for approximately 2 hours after administration to manage DIN-associated pain. However, pain control remains insufficient with standard opioid treatment.</p><p><strong>Methods: </strong>We treated a 3-year-old girl with high-risk neuroblastoma who received DIN after tandem transplantation. During the first treatment cycle, despite scheduled morphine therapy, she developed abdominal pain rated as 5 on the Faces Pain Scale (FPS; range 0-5, where 0 indicates no pain and 5 indicates the worst pain), indicating the need for higher doses, prolonged infusion, and additional bolus analgesia. The dosing period and DIN dosage in the second cycle were similar to those in the first cycle. To improve pain control during the second cycle, pregabalin was initiated at a dose of approximately 1 mg/kg/day 3 days prior to DIN administration.</p><p><strong>Results: </strong>This approach significantly reduced abdominal pain, with the maximum FPS score decreasing to 2.</p><p><strong>Conclusion: </strong>This case highlights that adding pregabalin to standard opioid therapy can contribute to improved management of DIN-induced pain.</p>","PeriodicalId":74394,"journal":{"name":"Palliative medicine reports","volume":"7 ","pages":"26892820261452103"},"PeriodicalIF":1.3000,"publicationDate":"2026-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13422623/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Palliative medicine reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/26892820261452103","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Opioids are commonly initiated prior to dinutuximab (DIN)-an anti-disialoganglioside 2 antibody used in the treatment of neuroblastoma-and continued for approximately 2 hours after administration to manage DIN-associated pain. However, pain control remains insufficient with standard opioid treatment.

Methods: We treated a 3-year-old girl with high-risk neuroblastoma who received DIN after tandem transplantation. During the first treatment cycle, despite scheduled morphine therapy, she developed abdominal pain rated as 5 on the Faces Pain Scale (FPS; range 0-5, where 0 indicates no pain and 5 indicates the worst pain), indicating the need for higher doses, prolonged infusion, and additional bolus analgesia. The dosing period and DIN dosage in the second cycle were similar to those in the first cycle. To improve pain control during the second cycle, pregabalin was initiated at a dose of approximately 1 mg/kg/day 3 days prior to DIN administration.

Results: This approach significantly reduced abdominal pain, with the maximum FPS score decreasing to 2.

Conclusion: This case highlights that adding pregabalin to standard opioid therapy can contribute to improved management of DIN-induced pain.

普瑞巴林与吗啡联合治疗缓解地努妥昔单抗引起的3岁女童疼痛1例。
简介:阿片类药物通常在迪努妥昔单抗(dinutuximab,一种用于治疗神经母细胞瘤的抗二异神经节苷脂2抗体)之前开始使用,并在给药后持续约2小时以治疗DIN相关疼痛。然而,标准的阿片类药物治疗仍然不足以控制疼痛。方法:我们治疗了一名3岁的高风险神经母细胞瘤女孩,她在串联移植后接受了DIN。在第一个治疗周期中,尽管有吗啡治疗计划,患者仍出现腹部疼痛,面部疼痛量表(FPS;范围0-5,0表示无疼痛,5表示疼痛最严重),表明需要更高剂量、延长输注时间和额外的大剂量镇痛。第二周期给药周期和DIN用量与第一周期相似。为了改善第二个周期的疼痛控制,普瑞巴林在给药前3天以约1mg /kg/天的剂量开始给药。结果:该入路明显减轻了腹痛,最大FPS评分降至2分。结论:本病例强调在标准阿片类药物治疗中加入普瑞巴林有助于改善丁嘌呤引起的疼痛的管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.20
自引率
0.00%
发文量
0
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书